Skip to content
Clinical Trials – home

PROPAFENONE HYDROCHLORIDE: A Comprehensive Guide for Patients

3 / 3
trials open to patients / all trials
5+
Countries

In short

Propafenone hydrochloride is an antiarrhythmic medication used to treat various heart rhythm disorders, particularly atrial fibrillation. Recent clinical trials have been exploring new formulations, applications, and comparisons of propafenone to better understand its efficacy and safety profile. These studies aim to improve treatment options for patients with cardiac arrhythmias and provide valuable insights into the drug's pharmacokinetics and pharmacodynamics.

At a glance

Study Types
Bioequivalence studies, comparative efficacy trials, pharmacokinetic studies
Formulations
Oral tablets, intravenous infusions, (R)-propafenone, (S)-propafenone
Patient Populations
Adults with atrial fibrillation, children with arrhythmias, patients with septic shock
Comparators
Amiodarone, beta-blockers (e.g., propranolol), placebo
Primary Outcomes
Arrhythmia reduction, pharmacokinetic parameters (Cmax, AUC), cardioversion rates
Safety Assessments
Adverse events, vital signs, ECG changes, laboratory tests
Novel Applications
Treatment of arrhythmias in septic shock, pediatric use

What is Propafenone Hydrochloride?

Propafenone Hydrochloride is a medication used to treat certain types of irregular heartbeats. It belongs to a class of drugs called antiarrhythmics, which help control heart rhythm problems. Propafenone is also known by brand names such as Rythmol SR®, Rhynorm, and Rytmonorm.

Medical Uses

Propafenone Hydrochloride is primarily used to treat the following conditions:

  • Atrial Fibrillation (AF): This is a common heart rhythm disorder where the upper chambers of the heart (atria) beat irregularly and often too fast. Propafenone helps to restore and maintain a normal heart rhythm in patients with AF.
  • Atrial Flutter: Another type of irregular heart rhythm that propafenone can help manage.
  • Ventricular Arrhythmias: These are irregular heartbeats originating from the lower chambers of the heart (ventricles). Propafenone can be used to treat certain types of ventricular arrhythmias.
  • Premature Ventricular Complexes (PVCs): These are extra, abnormal heartbeats that start in the ventricles. Propafenone has been studied for its effectiveness in reducing PVCs.

How Propafenone Works

Propafenone works by slowing the flow of electrical signals in the heart. This helps to stabilize the heart rhythm and prevent irregular heartbeats. It does this by blocking certain channels in heart cells that are responsible for the movement of ions like sodium and potassium. By altering these electrical signals, propafenone can help restore a normal heart rhythm.

Different Formulations

Propafenone Hydrochloride comes in different formulations:

  • Tablets: Regular tablets that are typically taken multiple times a day.
  • Extended-release capsules: These are designed to release the medication slowly over time, allowing for less frequent dosing.
  • Intravenous (IV) form: Used in hospital settings for rapid treatment of certain arrhythmias.

How It's Administered

The way propafenone is given depends on the formulation and the patient's specific condition:

  • Oral tablets: These are typically taken 2-3 times per day with or without food.
  • Extended-release capsules: Usually taken once or twice daily.
  • Intravenous administration: In hospital settings, propafenone may be given as an IV infusion over a period of time.

The dosage is determined by your doctor based on your specific condition, response to treatment, and other factors. It's important to take this medication exactly as prescribed and not to stop taking it without consulting your doctor.

Effectiveness

Research has shown that propafenone can be effective in treating various heart rhythm disorders:

  • In patients with atrial fibrillation, propafenone has been shown to be effective in converting the heart back to normal rhythm and preventing recurrence of AF.
  • Studies have compared propafenone to other antiarrhythmic drugs. For example, one study compared propafenone to dronedarone for maintaining normal heart rhythm after cardioversion (a procedure to restore normal heart rhythm) in patients with atrial fibrillation.
  • Propafenone has also shown effectiveness in reducing premature ventricular complexes (PVCs).

Potential Side Effects

Like all medications, propafenone can cause side effects. Common side effects may include:

  • Dizziness
  • Nausea
  • Unusual taste in the mouth
  • Constipation
  • Headache

More serious side effects can occur, although they are less common. These may include worsening of existing arrhythmias or development of new arrhythmias. It's important to report any unusual symptoms to your healthcare provider.

Ongoing Research

Research on propafenone is ongoing to better understand its effects and potential uses:

  • A study is investigating the pharmacokinetics (how the body processes the drug) of propafenone in children, as its use in pediatric patients is currently based mostly on clinical experience.
  • Another study is comparing the effectiveness of propafenone to amiodarone (another antiarrhythmic drug) in patients with septic shock who develop supraventricular arrhythmias.
  • Researchers are also studying different formulations of propafenone. One study is looking at the bioequivalence (how similar the effects are) of propafenone tablets manufactured at different sites.

These ongoing studies aim to improve our understanding of propafenone and optimize its use in different patient populations.

Questions people often ask

Conditions where Propafenone Hydrochloride is being studied

Each condition opens its own overview and trial list

Trials with Propafenone Hydrochloride

Recruiting trials first

See all 3 →
Quick filters
  • Participants:Adults
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).